New 'Super-Universal' CAR-T therapy targets tough blood cancers
NCT ID NCT07153068
Summary
This study is testing the safety and effectiveness of a new type of CAR-T cell therapy called supCD7 CART for adults with CD7-positive blood cancers that have returned or not responded to standard treatments. The trial will enroll up to 12 patients with either acute myeloid leukemia (AML) or T-cell leukemia/lymphoma (T-ALL/LBL). Researchers will give the modified immune cells by IV infusion to find the safest and most effective dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.